Introducing a Patient Navigation Program at a high-volume public cancer center in an LMIC context was associated—on our primary, symmetric six-month analysis—with a targeted, statistically significant reduction in the MOH approval → therapy start interval (T4; p = 0.008) for patients with early HER2-positive breast cancer starting dual anti-HER2 therapy. The gene discussed is ERBB2; the disease is breast carcinoma.